---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-000411"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:20:14.631450+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vivani reports NPM-115 preclinical weight loss comparable to Ozempic/Wegovy; prioritizes obesity

## Summary
- NPM-115 (exenatide implant) achieved ~20% weight loss in obese mice, similar to semaglutide injections.
- Disclosed semaglutide as API in NPM-139, a once-yearly implant for chronic weight management.
- Strategic shift to prioritize obesity implants; NPM-115 designed for twice-yearly dosing.
- IND for NPM-119 (type 2 diabetes) on clinical hold; expects to submit CMC info to FDA in H1 2024.
- Plans to submit IND for NPM-115 first-in-human obesity study later in 2024.

## SEC filing metadata
- accession: 0001753926-24-000411
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392624000411/0001753926-24-000411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392624000411/g084078_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-000411
- JSON: https://secwatch.observer/filing/0001753926-24-000411.json
- Plain text: https://secwatch.observer/filing/0001753926-24-000411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.